Who owns Protagonist Therapeutics, Inc (PTGX)? Elite investor 13F holders
4 tracked elite investors reported holding Protagonist Therapeutics, Inc as of 2026-09-30, including Renaissance Technologies LLC, Gotham Asset Management, Polen Capital Management, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
4 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Duquesne Family Office | PROTAGONIST THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| Renaissance Technologies LLC | PROTAGONIST THERAPEUTICS INC | SHARE | 2026-09-30 | 2026-11-12 00:00:00 | 10843881.00 USD | 76967.000000 | Shares | buy | Original filing |
| Gotham Asset Management | PROTAGONIST THERAPEUTICS INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 9199835.00 USD | 65298.000000 | Shares | add | Original filing |
| Polen Capital Management | PROTAGONIST THERAPEUTICS INC | SHARE | 2026-09-30 | 2026-11-13 00:00:00 | 2953477.00 USD | 20963.000000 | Shares | reduce | Original filing |
| Bridgewater Associates | PROTAGONIST THERAPEUTICS INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| D.E. Shaw | PROTAGONIST THERAPEUTICS INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 909163.00 USD | 6453.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.